Literature DB >> 26403211

Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.

K Sadowski1, K Kotulska1, R A Schwartz2,3, S Jóźwiak1,4.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic multisystem disorder associated with constitutive overactivation of the mammalian target of rapamycin (mTOR) pathway and characterized by development of benign tumours in various organs. mTOR inhibitors have proven to be effective in the targeted therapy of certain TSC-associated pathologies such as subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas (AMLs). Accumulating experimental and clinical data suggest that mTOR inhibitors might have a systemic, disease-modifying influence on affected individuals. This systematic review provides an analysis of available clinical data concerning systemic effect of mTOR inhibitors and the influence of mTOR inhibition on different manifestations of TSC in individual patients.
© 2015 European Academy of Dermatology and Venereology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26403211     DOI： 10.1111/jdv.13356

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


  5 in total

Review 1.  [Syndroms associated with benign skin tumors].

Authors:  George-Sorin Tiplica; Klaus Fritz; Alexandra Irina Butacu; Loredana Ungureanu; Carmen Maria Sălăvăstru
Journal:  Hautarzt       Date:  2022-01-25       Impact factor: 0.751

Review 2.  Neuroinflammatory targets and treatments for epilepsy validated in experimental models.

Authors:  Eleonora Aronica; Sebastian Bauer; Yuri Bozzi; Matteo Caleo; Raymond Dingledine; Jan A Gorter; David C Henshall; Daniela Kaufer; Sookyong Koh; Wolfgang Löscher; Jean-Pierre Louboutin; Michele Mishto; Braxton A Norwood; Eleonora Palma; Michael O Poulter; Gaetano Terrone; Annamaria Vezzani; Rafal M Kaminski
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

3.  Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?

Authors:  Claudia Santoro; Pia Bernardo; Antonietta Coppola; Umberto Pugliese; Mario Cirillo; Teresa Giugliano; Giulio Piluso; Giuseppe Cinalli; Salvatore Striano; Carmela Bravaccio; Silverio Perrotta
Journal:  Ital J Pediatr       Date:  2018-03-22       Impact factor: 2.638

Review 4.  Tuberous sclerosis complex: review based on new diagnostic criteria.

Authors:  Larissa Karine Leite Portocarrero; Klícia Novais Quental; Luciana Paula Samorano; Zilda Najjar Prado de Oliveira; Maria Cecília da Matta Rivitti-Machado
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

5.  Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.

Authors:  Ruben Marques; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D'Amato; Guillaume Beaure d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Rima Nabbout; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; John C Kingswood; Anna C Jansen
Journal:  Front Neurol       Date:  2019-10-25       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.